{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T02:02:07Z","timestamp":1777428127072,"version":"3.51.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,12]],"date-time":"2022-11-12T00:00:00Z","timestamp":1668211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,12]],"date-time":"2022-11-12T00:00:00Z","timestamp":1668211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["R01EY032561"],"award-info":[{"award-number":["R01EY032561"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NIH T32 EY007026"],"award-info":[{"award-number":["NIH T32 EY007026"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Pathologic retinal neovascularization is a potentially blinding consequence seen in many common diseases including diabetic retinopathy, retinopathy of prematurity, and retinal vaso-occlusive diseases. This study investigates epithelial membrane protein 2 (EMP2) and its role as a possible modulator of angiogenesis in human retinal pigment epithelium (RPE) under hypoxic conditions. To study its effects, the RPE cell line ARPE-19 was genetically modified to either overexpress EMP2 or knock down its levels, and RNA sequencing and western blot analysis was performed to confirm the changes in expression at the RNA and protein level, respectively. Protein expression was evaluated under both normoxic conditions or hypoxic stress. Capillary tube formation assays with human umbilical vein endothelial cells (HUVEC) were used to evaluate functional responses. EMP2 expression was found to positively correlate with expression of pro-angiogenic factors HIF1\u03b1 and VEGF at both mRNA and protein levels under hypoxic conditions. Mechanistically, EMP2\u00a0stabilized HIF1\u03b1 expression through downregulation of von Hippel Lindau protein (pVHL). EMP2 mediated changes in ARPE-19 cells were also found to alter the secretion of a paracrine factor(s) in conditioned media that can regulate HUVEC migration and capillary tube formation in in vitro functional angiogenesis assays. This study identifies EMP2 as a potential mediator of angiogenesis in a human RPE cell line. EMP2 levels positively correlate with pro-angiogenic mediators HIF1\u03b1 and VEGF, and mechanistically, EMP2 regulates HIF1\u03b1 through downregulation of pVHL. This study supports further investigation of EMP2 as a promising novel target for therapeutic treatment of pathologic neovascularization in the retina.<\/jats:p>","DOI":"10.1038\/s41598-022-22696-x","type":"journal-article","created":{"date-parts":[[2022,11,12]],"date-time":"2022-11-12T18:03:05Z","timestamp":1668276185000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Epithelial membrane protein 2 (EMP2) regulates hypoxia-induced angiogenesis in the adult retinal pigment epithelial cell lines"],"prefix":"10.1038","volume":"12","author":[{"given":"Michel","family":"Sun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nina","family":"Cherian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann M.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Aguirre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison","family":"Chu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Strawbridge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther S.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng-Chin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irena","family":"Tsui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynn K.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madhuri","family":"Wadehra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,12]]},"reference":[{"key":"22696_CR1","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s00109-013-0993-5","volume":"91","author":"PA Campochiaro","year":"2013","unstructured":"Campochiaro, P. A. Ocular neovascularization. J. Mol. Med. (Berl.) 91, 311\u2013321. https:\/\/doi.org\/10.1007\/s00109-013-0993-5 (2013).","journal-title":"J. Mol. Med. (Berl.)"},{"key":"22696_CR2","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s12041-009-0068-0","volume":"88","author":"Y Qazi","year":"2009","unstructured":"Qazi, Y., Maddula, S. & Ambati, B. K. Mediators of ocular angiogenesis. J. Genet. 88, 495\u2013515. https:\/\/doi.org\/10.1007\/s12041-009-0068-0 (2009).","journal-title":"J. Genet."},{"key":"22696_CR3","doi-asserted-by":"publisher","first-page":"C1358","DOI":"10.1152\/ajpcell.2001.280.6.C1358","volume":"280","author":"N Ferrara","year":"2001","unstructured":"Ferrara, N. Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am. J. Physiol. Cell Physiol. 280, C1358-1366. https:\/\/doi.org\/10.1152\/ajpcell.2001.280.6.C1358 (2001).","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"22696_CR4","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1167\/tvst.5.2.10","volume":"5","author":"N Ferrara","year":"2016","unstructured":"Ferrara, N. VEGF and intraocular neovascularization: From discovery to therapy. Transl. Vis. Sci. Technol. 5, 10. https:\/\/doi.org\/10.1167\/tvst.5.2.10 (2016).","journal-title":"Transl. Vis. Sci. Technol."},{"key":"22696_CR5","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1161\/ATVBAHA.108.181644","volume":"30","author":"GL Semenza","year":"2010","unstructured":"Semenza, G. L. Vascular responses to hypoxia and ischemia. Arterioscler. Thromb. Vasc. Biol. 30, 648\u2013652. https:\/\/doi.org\/10.1161\/ATVBAHA.108.181644 (2010).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"22696_CR6","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.cell.2012.01.021","volume":"148","author":"GL Semenza","year":"2012","unstructured":"Semenza, G. L. Hypoxia-inducible factors in physiology and medicine. Cell 148, 399\u2013408. https:\/\/doi.org\/10.1016\/j.cell.2012.01.021 (2012).","journal-title":"Cell"},{"key":"22696_CR7","doi-asserted-by":"publisher","first-page":"212532","DOI":"10.7573\/dic.212532","volume":"7","author":"Y Zhao","year":"2018","unstructured":"Zhao, Y. & Singh, R. P. The role of anti-vascular endothelial growth factor (anti-VEGF) in the management of proliferative diabetic retinopathy. Drugs Context 7, 212532. https:\/\/doi.org\/10.7573\/dic.212532 (2018).","journal-title":"Drugs Context"},{"key":"22696_CR8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1167\/iovs.61.2.3","volume":"61","author":"M Sun","year":"2020","unstructured":"Sun, M. et al. Epithelial membrane protein 2 (EMP2) promotes VEGF-Induced pathological neovascularization in murine oxygen-induced retinopathy. Invest. Ophthalmol. Vis. Sci. 61, 3\u20133. https:\/\/doi.org\/10.1167\/iovs.61.2.3 (2020).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"22696_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2020-315933","author":"TA Ciulla","year":"2020","unstructured":"Ciulla, T. A., Pollack, J. S. & Williams, D. F. Visual acuity outcomes and anti-VEGF therapy intensity in diabetic macular oedema: A real-world analysis of 28 658 patient eyes. Br. J. Ophthalmol. https:\/\/doi.org\/10.1136\/bjophthalmol-2020-315933 (2020).","journal-title":"Br. J. Ophthalmol."},{"key":"22696_CR10","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12886-017-0401-y","volume":"17","author":"F Ziemssen","year":"2017","unstructured":"Ziemssen, F. et al. Demographics of patients receiving Intravitreal anti-VEGF treatment in real-world practice: Healthcare research data versus randomized controlled trials. BMC Ophthalmol. 17, 7. https:\/\/doi.org\/10.1186\/s12886-017-0401-y (2017).","journal-title":"BMC Ophthalmol."},{"key":"22696_CR11","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/S0014-4800(03)00009-1","volume":"74","author":"M Wadehra","year":"2003","unstructured":"Wadehra, M., Sulur, G. G., Braun, J., Gordon, L. K. & Goodglick, L. Epithelial Membrane Protein-2 is expressed in discrete anatomical regions of the eye. Exp. Mol. Pathol. 74, 106\u2013112 (2003).","journal-title":"Exp. Mol. Pathol."},{"key":"22696_CR12","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1167\/iovs.12-11013","volume":"54","author":"SA Morales","year":"2013","unstructured":"Morales, S. A. et al. Epithelial membrane protein 2 controls VEGF expression in ARPE-19 cells. Invest. Ophthalmol. Vis. Sci. 54, 2367\u20132372 (2013).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"22696_CR13","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1167\/iovs.18-24345","volume":"60","author":"MM Sun","year":"2019","unstructured":"Sun, M. M. et al. Epithelial membrane protein-2 (EMP2) antibody blockade reduces corneal neovascularization in an in vivo ModelEMP2 blockade decreases corneal neovascularization. Invest. Ophthalmol. Vis. Sci. 60, 245\u2013254. https:\/\/doi.org\/10.1167\/iovs.18-24345 (2019).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"22696_CR14","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1158\/1535-7163.MCT-13-0199","volume":"13","author":"M Fu","year":"2014","unstructured":"Fu, M. et al. Rationale and preclinical efficacy of a novel anti-EMP2 antibody for the treatment of invasive breast cancer. Mol. Cancer Ther. 13, 902\u2013915. https:\/\/doi.org\/10.1158\/1535-7163.MCT-13-0199 (2014).","journal-title":"Mol. Cancer Ther."},{"key":"22696_CR15","doi-asserted-by":"publisher","first-page":"5369","DOI":"10.1038\/Onc.2012.622","volume":"32","author":"LK Gordon","year":"2013","unstructured":"Gordon, L. K. et al. EMP2 regulates angiogenesis in endometrial cancer cells through induction of VEGF. Oncogene 32, 5369\u20135376. https:\/\/doi.org\/10.1038\/Onc.2012.622 (2013).","journal-title":"Oncogene"},{"key":"22696_CR16","doi-asserted-by":"publisher","first-page":"e19945","DOI":"10.1371\/journal.pone.0019945","volume":"6","author":"M Fu","year":"2011","unstructured":"Fu, M. et al. Epithelial membrane protein-2 promotes endometrial tumor formation through activation of FAK and Src. PLoS ONE 6, e19945 (2011).","journal-title":"PLoS ONE"},{"key":"22696_CR17","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jocn.2017.06.044","volume":"44","author":"LK Chung","year":"2017","unstructured":"Chung, L. K. et al. Epithelial membrane protein 2: Molecular interactions and clinical implications. J. Clin. Neurosci. 44, 84\u201388. https:\/\/doi.org\/10.1016\/j.jocn.2017.06.044 (2017).","journal-title":"J. Clin. Neurosci."},{"key":"22696_CR18","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s11060-017-2507-8","volume":"134","author":"Y Qin","year":"2017","unstructured":"Qin, Y. et al. Epithelial membrane protein-2 (EMP2) promotes angiogenesis in glioblastoma multiforme. J. Neurooncol. 134, 29\u201340. https:\/\/doi.org\/10.1007\/s11060-017-2507-8 (2017).","journal-title":"J. Neurooncol."},{"key":"22696_CR19","doi-asserted-by":"publisher","first-page":"13974","DOI":"10.1074\/jbc.M113.543728","volume":"289","author":"Y Qin","year":"2014","unstructured":"Qin, Y. et al. Epithelial membrane protein-2 (EMP2) activates Src protein and is a novel therapeutic target for glioblastoma. J. Biol. Chem. 289, 13974\u201313985. https:\/\/doi.org\/10.1074\/jbc.M113.543728 (2014).","journal-title":"J. Biol. Chem."},{"key":"22696_CR20","doi-asserted-by":"publisher","first-page":"546","DOI":"10.3109\/02713683.2011.561468","volume":"36","author":"DG Telander","year":"2011","unstructured":"Telander, D. G., Morales, S. A., Mareninov, S., Forward, K. & Gordon, L. K. Epithelial membrane protein-2 (EMP2) and experimental proliferative vitreoretinopathy (PVR). Curr. Eye Res. 36, 546\u2013552. https:\/\/doi.org\/10.3109\/02713683.2011.561468 (2011).","journal-title":"Curr. Eye Res."},{"key":"22696_CR21","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1242\/dev.070813","volume":"139","author":"CAK Lange","year":"2012","unstructured":"Lange, C. A. K. et al. Von Hippel-Lindau protein in the RPE is essential for normal ocular growth and vascular development. Development 139, 2340\u20132350. https:\/\/doi.org\/10.1242\/dev.070813 (2012).","journal-title":"Development"},{"key":"22696_CR22","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1038\/s41418-018-0094-7","volume":"25","author":"M Barben","year":"2018","unstructured":"Barben, M. et al. Hif1a inactivation rescues photoreceptor degeneration induced by a chronic hypoxia-like stress. Cell Death Differ. 25, 2071\u20132085. https:\/\/doi.org\/10.1038\/s41418-018-0094-7 (2018).","journal-title":"Cell Death Differ."},{"key":"22696_CR23","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1124\/mol.106.027029","volume":"70","author":"Q Ke","year":"2006","unstructured":"Ke, Q. & Costa, M. Hypoxia-inducible factor-1 (HIF-1). Mol. Pharmacol. 70, 1469\u20131480. https:\/\/doi.org\/10.1124\/mol.106.027029 (2006).","journal-title":"Mol. Pharmacol."},{"key":"22696_CR24","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1002\/ijc.29519","volume":"138","author":"K Balamurugan","year":"2016","unstructured":"Balamurugan, K. HIF-1 at the crossroads of hypoxia, inflammation, and cancer. Int. J. Cancer 138, 1058\u20131066. https:\/\/doi.org\/10.1002\/ijc.29519 (2016).","journal-title":"Int. J. Cancer"},{"key":"22696_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/emm.2004.1","volume":"36","author":"JW Lee","year":"2004","unstructured":"Lee, J. W., Bae, S. H., Jeong, J. W., Kim, S. H. & Kim, K. W. Hypoxia-inducible factor (HIF-1)alpha: Its protein stability and biological functions. Exp. Mol. Med. 36, 1\u201312. https:\/\/doi.org\/10.1038\/emm.2004.1 (2004).","journal-title":"Exp. Mol. Med."},{"key":"22696_CR26","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1158\/1535-7163.mct-19-0850","volume":"19","author":"C Dillard","year":"2020","unstructured":"Dillard, C. et al. EMP2 is a novel regulator of stemness in breast cancer cells. Mol. Cancer Ther. 19, 1682\u20131695. https:\/\/doi.org\/10.1158\/1535-7163.mct-19-0850 (2020).","journal-title":"Mol. Cancer Ther."},{"key":"22696_CR27","doi-asserted-by":"publisher","first-page":"5793","DOI":"10.1038\/onc.2017.142","volume":"36","author":"MH Kiyohara","year":"2017","unstructured":"Kiyohara, M. H. et al. EMP2 is a novel therapeutic target for endometrial cancer stem cells. Oncogene 36, 5793\u20135807. https:\/\/doi.org\/10.1038\/onc.2017.142 (2017).","journal-title":"Oncogene"},{"key":"22696_CR28","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/j.oret.2018.06.004","volume":"2","author":"TA Ciulla","year":"2018","unstructured":"Ciulla, T. A., Bracha, P., Pollack, J. & Williams, D. F. Real-world outcomes of anti-vascular endothelial growth factor therapy in diabetic macular edema in the United States. Ophthalmol. Retina 2, 1179\u20131187. https:\/\/doi.org\/10.1016\/j.oret.2018.06.004 (2018).","journal-title":"Ophthalmol. Retina"},{"key":"22696_CR29","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/S0014-4835(03)00189-1","volume":"77","author":"ME Hartnett","year":"2003","unstructured":"Hartnett, M. E. et al. Retinal pigment epithelium and endothelial cell interaction causes retinal pigment epithelial barrier dysfunction via a soluble VEGF-dependent mechanism. Exp. Eye Res. 77, 593\u2013599. https:\/\/doi.org\/10.1016\/S0014-4835(03)00189-1 (2003).","journal-title":"Exp. Eye Res."},{"key":"22696_CR30","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1111\/aos.12415","volume":"92","author":"V Aaltonen","year":"2014","unstructured":"Aaltonen, V. et al. Hypoxic conditions stimulate the release of B-type natriuretic peptide from human retinal pigment epithelium cell culture. Acta Ophthalmol. 92, 740\u2013744. https:\/\/doi.org\/10.1111\/aos.12415 (2014).","journal-title":"Acta Ophthalmol."},{"key":"22696_CR31","unstructured":"Kolde, R. pheatmap: Pretty Heatmaps. R package version 1.0. 12. CRAN. https:\/\/CRAN.R-project.org\/package=pheatmap (2019)."},{"key":"22696_CR32","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1093\/bioinformatics\/btv300","volume":"31","author":"W Walter","year":"2015","unstructured":"Walter, W., S\u00e1nchez-Cabo, F. & Ricote, M. GOplot: An R package for visually combining expression data with functional analysis. Bioinformatics 31, 2912\u20132914 (2015).","journal-title":"Bioinformatics"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-22696-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-22696-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-22696-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,12]],"date-time":"2022-11-12T18:07:27Z","timestamp":1668276447000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-22696-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,12]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["22696"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-22696-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,12]]},"assertion":[{"value":"28 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.W. and L.K.G are inventors on the University of California patents related to anti-EMP2 mAbs. M.W. was also a scientific advisor for Oncoresponse. No other authors have competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19432"}}